JP2006515750A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515750A5
JP2006515750A5 JP2004562588A JP2004562588A JP2006515750A5 JP 2006515750 A5 JP2006515750 A5 JP 2006515750A5 JP 2004562588 A JP2004562588 A JP 2004562588A JP 2004562588 A JP2004562588 A JP 2004562588A JP 2006515750 A5 JP2006515750 A5 JP 2006515750A5
Authority
JP
Japan
Prior art keywords
antibody
seq
multivalent
construct
antibody construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004562588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515750A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/041393 external-priority patent/WO2004058191A2/en
Publication of JP2006515750A publication Critical patent/JP2006515750A/ja
Publication of JP2006515750A5 publication Critical patent/JP2006515750A5/ja
Pending legal-status Critical Current

Links

JP2004562588A 2002-12-20 2003-12-22 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療 Pending JP2006515750A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43515402P 2002-12-20 2002-12-20
PCT/US2003/041393 WO2004058191A2 (en) 2002-12-20 2003-12-22 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2006515750A JP2006515750A (ja) 2006-06-08
JP2006515750A5 true JP2006515750A5 (https=) 2007-04-05

Family

ID=32682169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004562588A Pending JP2006515750A (ja) 2002-12-20 2003-12-22 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療

Country Status (8)

Country Link
US (1) US20060104971A1 (https=)
EP (1) EP1583503A4 (https=)
JP (1) JP2006515750A (https=)
CN (1) CN100473664C (https=)
AU (1) AU2003299984A1 (https=)
CA (1) CA2511013A1 (https=)
NO (1) NO20053530L (https=)
WO (1) WO2004058191A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
NZ544924A (en) * 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
CA2646508A1 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
AU2016231617B2 (en) * 2006-06-12 2018-08-23 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
AU2014200661B2 (en) * 2006-06-12 2016-06-30 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
KR20100058509A (ko) * 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
KR100967623B1 (ko) * 2008-02-22 2010-07-05 전남대학교산학협력단 림포톡신을 포함하는 자궁경부암 예방 또는 치료용 조성물
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
WO2013166099A1 (en) * 2012-05-01 2013-11-07 Glaxosmithkline Llc Novel antibodies
AU2014210908B2 (en) * 2013-02-04 2019-02-14 University Of Huddersfield Composition comprising a TNFR agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma
TWI700295B (zh) * 2013-12-16 2020-08-01 馬來西亞商Ｍａｂ探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
MX389194B (es) 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
CN112912400B (zh) 2018-10-19 2025-05-30 明尼苏达大学董事会 Nk接合子分子及其使用方法
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (ja) * 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669941A (en) * 1898-12-17 1901-03-12 Electric Axle Light & Power Company Electric switch.
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2150249A1 (en) * 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
KR100475492B1 (ko) * 1995-01-26 2005-03-14 바이오겐 아이덱 엠에이 인코포레이티드 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
JP2003531588A (ja) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
ATE463745T1 (de) * 2000-06-30 2010-04-15 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
AU8678501A (en) * 2000-08-24 2002-03-04 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7642242B2 (en) * 2002-03-05 2010-01-05 Genentech, Inc. PRO34128 polypeptides
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Similar Documents

Publication Publication Date Title
JP2006515750A5 (https=)
JP2006515750A (ja) 多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療
US7947271B2 (en) Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents
US10100119B2 (en) Anti-human interleukin-1 receptor accessory protein antibody and its use for treating cancer
JP2022046651A (ja) ４－１ｂｂ結合分子
US7429645B2 (en) Humanized anti-lymphotoxin beta receptor antibodies
US20060134102A1 (en) Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
JP2006513225A5 (https=)
US20090175866A1 (en) Treatment of b-cell malignancies
TW202417483A (zh) 結合nkg2d、cd16及ceacam5之蛋白質
CN116059377A (zh) 抗ox40抗体在联合用药中的应用
WO2024240247A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies
JP2025540215A (ja) Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法
EA047697B1 (ru) Способы лечения рака с использованием антител к ox40 в комбинации с антителами к pd1 или к pdl1
MXPA06010891A (en) Receptor coupling agents and therapeutic uses thereof